Antimicrobial

Sonoma Pharmaceuticals Reports Second Fiscal Quarter 2024 Financial Results

Gross profit percentage of 36% for the quarter, up 1% from first fiscal quarter 2024Total operating expenses decreased for the…

1 year ago

Sonoma Pharmaceuticals Announces U.S. Launch of Next Generation Advanced Solution for Pulse Lavage Irrigation at the Symposium on Advanced Wound Care Fall Conference

BOULDER, CO / ACCESSWIRE / November 3, 2023 / Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader developing and producing…

1 year ago

Covalon Presents Innovative Solutions Used in Top Hospitals at the Association for Vascular Access (AVA) Annual Scientific Meeting in Portland, OR

Visit Covalon at booth 715 at the AVA Conference and Exhibit to discover true compassionate vascular access solutionsMISSISSAUGA, Ontario--(BUSINESS WIRE)--Covalon…

1 year ago

Sona Provides Corporate Update on Operating Activities

Halifax, Nova Scotia--(Newsfile Corp. - October 12, 2023) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company" or "Sona"),…

1 year ago

Covalon to Showcase Innovative Solutions at the Prestigious ANCC National Magnet Conference in Chicago

Discover Novel Compassionate Care Solutions at Booth 1835, McCormick Place Convention CenterMISSISSAUGA, Ontario--(BUSINESS WIRE)--Covalon Technologies Ltd. (the “Company” or “Covalon”)…

1 year ago

CorMedix Inc. Announces Abstract Presentation at Upcoming IDWeek Conference

BERKELEY HEIGHTS, N.J., Oct. 11, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and…

1 year ago

Cidara Therapeutics Presents New Preclinical and Clinical Data on Novel Drug-Fc Conjugate CD388 at IDWeek 2023

SAN DIEGO, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform…

1 year ago

Spexis provides business update and announces financial results for the first half of 2023

Ad hoc announcement pursuant to Art. 53 LR Balixafortide, a potent CXCR4 inhibitor, to be evaluated for the treatment of…

1 year ago